Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - teriparatide, quantity: 250 microgram - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate; hydrochloric acid; mannitol; sodium hydroxide; water for injections; metacresol - forteo is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures. forteo is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

Ireland - English - HPRA (Health Products Regulatory Authority)

forte healthcare ltd - bovine rotavirus, inactivated; bovine coronavirus, inactivated; escherichia coli (inactivated) - emulsion for injection - bovine rotavirus + bovine coronavirus + escherichia

Ireland - English - HPRA (Health Products Regulatory Authority)

forte healthcare ltd - bovine coronavirus strain c-197 (inactivated); bovine rotavirus strain tm-91, serotype g6p1 (inactivated). ; escherichia coli strain ec/17, (inactivated) expressing f5(k99) adhesin - emulsion for injection - . - bovine rotavirus + bovine coronavirus + escherichia - cattle - immunological - inactivated vaccine

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - teriparatide -

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - teriparatide (rdna origin) - injection, solution - 750 mcg/3 ml - teriparatide (rdna origin) 750 mcg/3 ml

European Union - English - EMA (European Medicines Agency)

forte healthcare limited - fluoxetine - psychoanaleptics - dogs - as an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate behaviours (vocalisation and inappropriate defecation and / or urination) and only in combination with behavioural-modification techniques.

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - amoxicillin; clavulanic acid - film-coated tablet - 500 /125 milligram(s) - combinations of penicillins, incl. beta-lactamase inhibitors; amoxicillin and enzyme inhibitor

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg; doxylamine succinate, quantity: 5 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: stearic acid; crospovidone; glyceryl monostearate; magnesium stearate; lactose monohydrate; povidone; pregelatinised maize starch - dolased forte is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

eli lilly (s.a.) (pty) ltd - injection - see ingredients - each 1,0 ml solution contains teriparatide 250,0 ug

Ireland - English - HPRA (Health Products Regulatory Authority)

forte healthcare ltd - bovine rotavirus strain tm-91 (inactivated), bovine coronavirus strain c-197 (inactivated), escherichia coli adhesion f5 (k99) (inactivated) - emulsion for injection - unknown - inactivated bovine rotavirus vaccine + inactivated bovine coronavirus vaccine + inactivated escheri - bovine - immunological - inactivated vaccine